诺诚健华(688428):诺诚健华医药有限公司2027年度“提质增效重回报”2.0行动方案(英文版)

时间:2026年11月20日 18:36:46 中财网
原标题:诺诚健华:诺诚健华医药有限公司2027年度“提质增效重回报”2.0行动方案(英文版)

InnoCarePharmaLimited
2027“QualityImprovement,EfficiencyEnhancement
andHighReturn”2.0ActionPlan
InnoCarePharmaLimited(the“Company”),inordertoimplementtherelevantrequirementsoftheStateCouncil’sOpinionsonFurtherImprovingQualityofListedCompanies, actively responds to the Shanghai Stock Exchange’s Proposal onLaunchingthe“QualityImprovement,EfficiencyEnhancementandHighReturn”2.0SpecialActionforSSE-ListedCompaniesandtheaccompanyingmodeltexts,practicesthe “investor-oriented” development philosophy, effectively fulfills the primaryresponsibilities of a listed company, and promotes the Company’s high-qualitydevelopment.Onthebasisoftheoriginalactionplan,theCompanyhasformulatedthe2027“QualityImprovement,EfficiencyEnhancementandHighReturn”2.0ActionPlan,whichisherebyreportedasfollows:
I. OverviewoftheCompany’sOperations
TheCompanyisaninnovativebiopharmaceuticalenterprisedrivenbyoutstandingin-houseR&Dcapabilities,focusingonareaswithsignificantunmetclinicalneeds,suchasoncologyandautoimmunediseases,anddevelopingbest-in-classorfirst-in-classdrugswithbreakthroughpotential.TheCompany’sexistingpipelinedrugscovermultipleinnovativetargetsandindicationswithstrongmarketprospects,includingsmall molecules, monoclonal antibodies, bispecific antibodies andADCs for thetreatmentofhemato-oncology,variousautoimmunediseasesandsolidtumors.LedbyamanagementteamwithextensiveexperienceinR&D,manufacturingandcommercialization,theCompanyhasbuiltanintegratedbiopharmaceuticalplatformthatbalancesR&Dqualityandspeed,andhasestablishedaproductpipelinecoveringmultiplehighlypromisingpopulartargets,committedtodevelopingandprovidingpatientswithmultipleinnovativedrugsandtherapies.
(I)AnalysisofOperatingPerformancebySegment
1. HematologicOncology
HematologiconcologyistheCompany’scurrentcoregrowthengine,supportedbycommercializedproducts,continuouslyexpandingindicationsandadifferentiatedpipelineofnext-generationtherapies.
Orelabrutinib has demonstrated strong commercial momentum in 2026.Theapprovalandreimbursementcoverageofthe1LCLL/SLLindicationfurtherexpandedpatientaccessibilityandstrengtheneditsmarketposition.Inaddition,orelabrutinibremainstheonlyBTKinhibitorapprovedinChinaforr/rMZL,furtherreinforcingitsdifferentiatedprofile.Orelabrutinibhasfurtherextendeditsglobalregistrationfootprint,withapprovalgrantedforther/rMCLindicationinAustraliaandther/rMZLindicationinSingapore,furthervalidatingitsdifferentiatedclinicalprofileandreinforcingitspotentialasagloballycompetitiveBTKinhibitor.
TafasitamabwasapprovedbytheNMPAin2025foradultpatientswithr/rDLBCLwho are not eligible for ASCT. The product further enriched the Company’shematologiconcologyportfolioandclarifieditsclinicalpositioningthroughupdatedrecommendationsintheChineseSocietyofClinicalOncology(CSCO)GuidelinesfortheDiagnosisandTreatmentofMalignantLymphoma.TafasitamabincombinationwithlenalidomidewasupgradedtoaClassIrecommendedregimenforsecond-lineandlatertreatmentofDLBCL,whiletafasitamabincombinationwithrituximabandlenalidomide was newly included as a Class I recommended regimen forrelapsed/refractoryfollicularlymphoma(r/rFL).
Mesutoclax(ICP-248)hascontinuedtoadvanceasastrategicgrowthpillarofthehematologyfranchise.MultipleregistrationaltrialsareprogressingacrossCLL/SLL,MCL,MZLandAML.Updatedclinicaldatapresentedatthe2026ASCOAnnualMeetingfurthersupportedthepotentialofmesutoclax(ICP-248)acrossmultiplenon-Hodgkin lymphomas and myeloid malignancies. With an expanding commercialfoundation and multiple late-stage clinical programs advancing, the Company ispositionedtofurtherstrengthenitsleadershipinhematologiconcology.2. AutoimmuneDiseases
In autoimmune diseases, the Company has established a differentiated andincreasinglymatureportfoliotargetingbothB-cellandT-cell-mediatedpathways,anchoredbyoralsmall-moleculeinnovation.
(1)Orelabrutinibhasmaderapidclinicalprogressacrossmultipleautoimmuneindications:
①ITP:TheNewDrugApplication(NDA)submissionwasacceptedbythe
NMPAinMay2026followingthecompletionoftheregistrationalPhaseIIIstudy.②SLE:PositivePhaseIIbdatapresentedatEULAR2026supportedcontinuedPhaseIIIclinicaldevelopment,andpatientenrollmentinthePhaseIIIstudyiscurrentlyongoing.
③MS:GlobalPhaseIIIprogramsinPPMSandnaSPMSareongoingthrough
thecollaborationwithZenasBioPharma,Inc.,withongoingpatientenrollment.(2)Soficitinib(ICP-332)hascontinuedtoadvanceasakeyT-cellpathwayasset:①The Phase III registrational trial in moderate-to-severe atopic dermatitiscompleted patient enrollment, achieved its primary endpoint and multiple keysecondaryendpoints.
②ThePhaseIIportionofthePhaseII/IIIprograminnon-segmentalvitiligoachieveditsprespecifiedprimaryendpoint,withPhaseIIIstudydesigndiscussionsongoingwiththeCDE.
③Additional indications, including CSU, psoriasis and PN, continued toprogresssteadily.
(3)Fadeucravacitinib(ICP-488),aselectiveallostericTYK2inhibitor,hasfurtherstrengthenedtheCompany’sautoimmunepipeline:
①ThePhaseIIIpsoriasisstudycompletedpatientenrollmentandachieveditsprimaryendpoint.
②ThePhaseIIstudiesincutaneouslupuserythematosus(CLE)andSj?gren’ssyndromeprogressedsmoothly,withclinicaldevelopmentadvancingcomprehensivelyacrossmultipleautoimmuneindications.
Beyondlate-stageprograms,theCompanycontinuedtoexpanditsautoimmunepipeline.ICP-538,aVAV1-targetedcompound,enteredclinicaldevelopmentwithPhaseISAD/MADcohortsongoing.ICP-054,anoralIL-17smallmolecule,initiatedPhaseIclinicaldevelopment,withSAD/MADescalationunderway.ICP-B161(aTL1A/IL-23p19bispecificantibody)wasapprovedforclinicaltrialinOctober2026forthetreatmentofinflammatoryboweldisease(IBD)andotherautoimmunediseases.3. SolidTumors
Insolidtumors,theCompanyisbuildingacompetitiveportfoliocombiningtargetedtherapiesandproprietaryADCtechnologies.
Zurletrectinib(ICP-723)receivedNMPAapprovalforNTRKfusion-positivesolidtumors,markingtheapprovalandlaunchoftheCompany’sfirstsolidtumortherapy;theNDAforthepediatricindicationhasalsobeensubmitted.
ThreecandidatesfromtheCompany’sproprietaryADCplatformhaveenteredtheclinicalstage.ICP-B794,aB7-H3-targetedADC,isdemonstratingencouragingearlysafetyandpharmacokineticsignals.ICP-B208,aCDH17-targetedADC,isinPhaseIclinicaldoseescalation.ICP-B381,adifferentiatedPSMA/STEAP1dual-targetingADC,hascompletedfirst-patientenrollmentinitsPhaseIclinicaltrialforthetreatmentofprostatecancerandothersolidtumors.
(II)KeyFinancialIndicatorsforthePastThreeYears
Unit:RMBtenthousand Currency:RMB

Operating Indicators2023 (Audited)2024 (Audited)2025 (Audited)FirstThree Quartersof 2026 (Unaudited)
Operating revenue73,853.70100,944.80237,490.60209,910.45
Net-63,126.29-44,063.3064,246.7365,569.83
profit/(loss) attributable to ownersofthe parent    
Net profit/(loss) attributable to ownersofthe parent after deducting non-recurring gains and losses-62,584.46-44,022.0155,339.3658,603.82
Totalassets991,999.59940,749.371,082,360.091,147,571.71
Netassets714,784.87672,530.14772,682.32819,652.05
Gross profit margin(%)82.6186.2991.9591.19
R&D investment75,725.3181,460.9495,161.8378,505.28
R&D investment as a percentage of operating revenue(%)102.5380.7040.0737.40
Year-on-year growthrateof R&D investment (%)16.737.5716.8216.12
TrendsandReasonsforChangesinKeyIndicators:
1. OperatingRevenue:
During2023–2024,thegrowthintheCompany’soperatingrevenuewasprimarilydrivenbythecoreproductorelabrutinib.FollowingtherenewalofNRDLandapproval of new indications, orelabrutinib achieved continuous hospitalpenetrationandincreasedprescriptionvolume,representingasteadyramp-upphase in the commercialization of such drug. Since 2025, the inclusion oforelabrutinibforfirst-lineCLL/SLLindicationintotheNRDLhasdrivensalesvolume,whiletheapprovalandlaunchoftafasitamabandzurletrectinibformedamulti-productcommercialportfolio.Coupledwiththerecognitionofsignificantmilestone income from global out-licensing, operating revenue for the yearincreasedby135.3%year-on-year.Inthefirstthreequartersof2026,orelabrutinib,tafasitamabandzurletrectinibcontinuedtocontributepharmaceuticalrevenue,whilesubsequentmilestonesfrompreviousoverseascollaborationscontinuedtoberealized,resultinginan88.2%year-on-yearincreaseinoperatingrevenue.Overall,theCompany’srevenuegrowthstemmedfromthecombinedeffectsofclinical translation of in-house innovation pipelines, construction ofcommercialization systems, and global asset out-licensing, with continuousimprovementinoperationalquality.
2. NetProfit/(Loss)AttributabletoOwnersoftheParentandAfterDeductingNon-recurringGainsandLosses
During2023–2024,theCompanywasinthephaseofcommercializationramp-upfor innovative drugs and continuous pipeline investment, with net profitattributabletoownersoftheparentandafterdeductingnon-recurringgainsandlossesbeingnegative.However,withthesalesvolumegrowthofcoreproductsandrefinedcostcontrol,thelossmarginnarrowedyearbyyear.In2025,relyingonthesalesvolumegrowthofcoredrugsandtherecognitionofglobalout-licensingmilestoneincome,theCompanyachievedprofitabilityforthefirsttimeinbothnetprofitattributabletoownersoftheparentandafterdeductingnon-recurringgainsandlosses.Inthefirstthreequartersof2026,withthefurtherenrichmentoftheproductmatrixandcontinuousrealizationofincomefromout-licensingbusiness,profitabilitycontinued.ThemaindriversoftheCompany’sprofitchangesarethematuringcommercializationofinnovativedrugs,valuerealization from global business development, and improved quality andefficiency of costs. The profit is mainly from principal businesses, namelypharmaceuticalsalesrevenueandbusinessdevelopmentincome,withthechangetrendofnetprofitattributabletoownersoftheparentafterdeductingnon-recurringgainsandlossesbeinggenerallyconsistentwiththatofnetprofitattributabletoownersoftheparent.
3. TotalAssetsandNetAssets
During2023–2024,theCompanywasinthepre-profitabilitystagefeaturingcommercializationramp-upandcontinuouspipelineinvestment.Operatinglossesledtoadecreaseinretainedearnings,leadingtoaslightdeclineintotalassetsandnetassetsattributabletoownersoftheparentin2024.In2025,benefitingfromthesalesvolumegrowthofcoredrugsandrealizationofglobalout-licensingmilestoneincome,theCompanyachievedannualprofitabilityforthefirsttime,withoperatingcashflowturningpositive.Endogenousprofitaccumulationdrovetheincreaseinnetassets,resultingingrowthintotalassetsandnetassets.Inthefirst three quarters of 2026, with continuous realization of profits, retainedearningscontinuedtoincrease,andtheassetscalemaintainedsteadygrowth.TheCompany’sassetstructureismainlycomposedofcashandcashequivalents,financialassets,andoperatingreceivables,witharelativelylowproportionoflong-termassets.Endogenouscapitalaccumulationdrivenbyprofitabilityisthecorepathforthecurrentgrowthinnetassets.TheCompanyadherestoalow-leverageoperatingstrategy,prioritizingthesupportofbusinessexpansionthroughoperatingprofitsandoperatingcashflow,resultinginacontinuouslyrobustfinancialstructure.
4. GrossProfitMargin
During2023–2024,thesalesvolumegrowthofthecoreproductorelabrutinibunlockedproductionscaleeffects,liftingtheprofitabilityofsingledrugproducts.In2025,thegrossprofitmarginincreasedsignificantly,primarilyduetotheinclusionofhigh-marginglobalpipelineout-licensingmilestoneincomeintooperatingrevenue.Theoptimizationofrevenuestructure,coupledwithcontinuousimprovementofpharmaceuticalproductioncosts,significantlyimprovedearningsquality. In the first three quarters of 2026, with the further expansion ofpharmaceuticalsalesscaleandfurtherdiversificationofrevenuestructure,theconsolidatedgrossprofitmarginremainedrelativelystable,layingasolidearningsfoundation.
5. R&DInvestment,R&DInvestmentasaPercentageofOperatingRevenue,andYear-on-YearGrowthRateofR&DInvestment
From 2023 to the first three quarters of 2026, the Company’s total R&Dinvestmentcontinuedtoincrease,witharelativelystableyear-on-yeargrowthrateinR&Dinvestment.ThecoverageofR&Dinvestmentbyrevenuecontinuedtostrengthen,withR&Dinvestmentasapercentageofoperatingrevenuedecreasingfrom102.53%in2023to37.40%inthefirstthreequartersof2026.Intermsofqualityandefficiencyimprovement,theCompanycontinuouslyoptimizestheallocation and precision of R&D resources, pushes forward innovation oftechnologyplatformsandinvestmentsinclinicaltrialsaimedatacceleratingtransformation. Meanwhile, commercialization and business developmentbusinesseshavebroughtrapidrevenuegrowth,withtheoutputefficiencyofR&Dinvestment continuously improving, achieving a dynamic balance betweeninnovationinvestmentandoperationalbenefits.
II.Management’sDiscussionandAnalysisontheCompany’sCurrentStatusofQualityImprovement,EfficiencyEnhancementandHighReturn
(I)AnalysisofOperatingIndicators
1. SelectionofOperatingIndicators

Indicators2025FirstThree Quartersof20262027Target
Growth rate of R&D investment16.82%16.12%≥10%
Numberofnewclinical trials initiated (including Phase I–III clinicaltrials,measured by first patient enrollment)1314≥8
2. DescriptionofOperatingIndicatorsandImprovementMeasures
(1)GrowthRateofR&DInvestment
TheinnovativedrugindustryischaracterizedbylongR&Dcycles,highupfrontinvestments,anddelayedvaluerealization.TheCompanyiscurrentlyinarapiddevelopmentphasewhereR&Dpipelinesareenteringacriticalclinicalramp-up.R&Dinvestmentisessentiallyastrategicinvestmentinfutureproducts,pipelineassets,andlong-termcompetitiveness.QualityandefficiencyimprovementdoesnotmeancompressingR&Dinvestment;thecoreistoguidethegrowthofR&Dinvestment to match the pipeline strategic layout and commercializationconversionrhythm.UnderthepremiseofmaintainingcontinuousR&Dgrowth,theconversionefficiencyofeveryunitofR&Dinvestmentwillbeenhanced,achievingboth“investmentgrowthandefficiencyimprovement”.Insummary,theCompanywillcontinuetoinvestinR&Din2027,withaplannedyear-on-yeargrowthofnolessthan10%.
ImprovementMeasuresfor“InvestmentGrowthandEfficiencyImprovement”inR&DExpenses:
Normalizedpipelinereview,focusingoncoreprojectinvestment:Regularlyreviewpipelineprojects,prioritizingresourceallocationforimportantprojectswith high priority; timely adjust early-stage projects with progress belowexpectationsorweakcompetitiveadvantages,concentratingfundsonprojectswithhighconversionpotential.
Refinedprojectbudgetcontrol,trackingactualprogress:Preparebudgetsseparately for each project, strengthen process management during actualexecution,anduseprojectprogressasthebasisforsubsequentbudgetadjustments.SimultaneouslytracktheactualsituationofR&Dinvestment,timelyorganizeinternalreviewsandadjustments,andregularlyreporttheeffectivenessofR&Dinvestmenttomanagement.
Optimize external procurement management related to R&D expenses:ConductframeworkpricecomparisonsforcommonCROandotheroutsourcedservices,strivingtosaveunitservicecostsunderthepremiseofincreasinginvestmentscale.
(2)NumberofNewClinicalTrialsInitiated
TheCompanyisaninnovativebiopharmaceuticalenterprisedrivenbyoutstandingin-houseR&Dcapabilitiesasitscoredrivingforce,withaportfoliocoveringmultipleinnovativetargetsandindicationswithsignificantmarketprospects,includingsmallmolecule drugs, monoclonal antibodies, bispecific antibodies and ADCs for thetreatment of hemato-oncology, various autoimmune diseases and solid tumors.InnovativedrugR&Discharacterizedbylongcycles,highcapitalinvestmentandprominenttechnicalbarriers;thescaleofR&DinvestmentandtheclinicaltriallayoutcanobjectivelyreflectthepaceofpipelineadvancementandarecoreobservationalindicatorsforassessingtheCompany’slong-termgrowthpotential.In2027,theCompanywillcontinuetoadvancetheR&Dandclinicaldevelopmentofvariousinnovativedrugs,andplanstoinitiatenofewerthaneightnewclinicaltrials(includingPhaseI–IIIclinicaltrials,measuredbyfirstpatientenrollment).(II)AnalysisofReturnIndicators
1.SelectionofReturnIndicators

IndicatorsCurrentStatus2027Target
Investor relationsCurrently, the Company hasContinuously optimize
managementestablished a regular mechanism whereby results briefings are held after the disclosure of each periodic report.communication channels for small and medium-sized investors and improve the quality of communication, regularly carry out investor engagementactivities,andhold no fewer than four results briefings.
ESGmanagementThe Company has disclosed ESG-relatedreportsforseven consecutiveyears.Improve the system for collecting, compiling and disclosing ESG data and information,andcompletethe disclosure of the 2026 ESG Report with high quality; continue to optimize the Company’s greenhouse gas accountingsystemandexpand the scope of carbon emission measurement for Scope 3 categories.
2. DescriptionofReturnIndicatorsandImprovementMeasures
(1)InvestorRelationsManagement
TheCompanyhasestablisheda“three-in-one”communicationchannel:regularresponsesviatheSSEe-InteractionPlatform,dedicatedstaffingoftheinvestorhotline,anda24-hourIRemailresponsemechanism.TheCompanyachieveda100%responseratetoinvestorquestionsontheSSEe-InteractionPlatform,effectivelysafeguardingtherighttoknowandparticipateofsmallandmedium-sizedinvestors.TheCompanyproactivelycontactsinvestorsuponthepublicationofperiodicreportsandmajorannouncements.In2026,theCompanyheldthe2025AnnualResultsBriefing,the2026FirstQuarterResultsBriefing,the2026InterimResultsBriefingandthe2026ThirdQuarterResultsBriefing,withallcoremanagementattendingandcommunicatingonline with small and medium-sized investors, establishing a regular meetingmechanism.Inaddition,on14May2026,JisongCui,ChairpersonoftheBoardandChiefExecutiveOfficeroftheCompany,participatedbyvideointhe“DialoguewithGrowth”2025Annualand2026FirstQuarterCollectiveResultsBriefingorganizedbytheSSE,engaginginin-depthexchangeswithindustryleadersonperformancedelivery,profitabilityinflectionpoints,pipelineR&D,overseasexpansion,AIempowermentandotheraspects.TheexchangesshowcasedthecriticaltransitionofChina’sinnovativedrugindustryfromR&Dinvestmenttovaluerealization,shedlightonthelogicofindustrygrowthandtheglobalcompetitivelandscape,anddeliveredauthenticandcutting-edgeindustryinsightstoinvestors.In2027,theCompanywillcontinuetooptimizecommunicationchannelswithandqualityofcommunicationforsmallandmedium-sizedinvestors,regularlycarryoutinvestorengagementactivities,andholdnofewerthanfourresultsbriefings.
(2)ESGManagement
TheCompanyhasestablishedatop-downESGmanagementstructurewithclearresponsibilitiesandauthorities,comprisingtheBoardastheleadingbody,theESGworkinggroupasthecoremanagementlayer,andthefunctionaldepartmentsastheprimaryimplementation units.TheCompany haspublished ESG reports in bothChineseandEnglishforsevenconsecutiveyears.WithoutstandingESGperformance,theCompanywasselectedforthefirsttimeinS&PGlobal’s2026SustainabilityYearbook(ChinaEdition).In2027,theCompanywillcontinuetoimprovethesystemforcollecting,compilinganddisclosingESGdataandinformation,andcompletethedisclosureofthe2026ESGReportwithhighquality,whilefurtheroptimizingtheCompany’sgreenhousegasaccountingsystemandexpandingthescopeofcarbonemissionmeasurementforScope3categories.
(III)AnalysisofComplianceIndicators
1.SelectionofComplianceIndicators

IndicatorsCurrentStatus2027Target
Corporate governance policy developmentInresponsetonewregulatory requirements, the Company revised the Articles of Association and other five internal governance policies and formulated one new internalgovernancepolicy.Continuouslytrackchangesin laws, regulations and regulatory rules, and update the systems relating to corporate governance in a timelymanner.
Information disclosureTheCompanyhascontinued to implement high-standard management of information disclosure, optimize the presentation of announcements,continuously enhance the readability of information disclosure, and improvetheeffectivenessof deliveringvalueinformation. TheCompanyhasreceivedan “A” rating in the Shanghai StockExchange’sinformation disclosureworkevaluationfor twoconsecutiveyears.Strengthen the quality of information disclosure, tighten the review of announcement preparation, and ensure zero major disclosure errors and zero corrections. Within the compliance framework, optimizetheinterpretationof operating information, enhance the clarity of indicators and strategic narratives,reduceinformation asymmetry, and stabilize marketexpectations.
Performance of dutiesbytheAudit Committee of the BoardFullyperformthereviewand oversight responsibilities of theAudit Committee of the Board over the Company’s financialreports,internaland externalaudit,internalcontrolThe Audit Committee shall convene no fewer than four meetingsthroughouttheyear and perform its review and oversight responsibilities in respect of matters such as
 andothermatters.control work during the annual financial report audit period.Themembersofthe AuditCommitteeshallreceive trainingatleasttwiceayear.
2.DescriptionofComplianceIndicatorsandImprovementMeasures
(1)CorporateGovernancePolicyDevelopment
TheCompany,instrictcompliancewiththerequirementsoftheSecuritiesLawofthePeople’sRepublicofChina,theRulesGoverningtheListingofStocksontheSTARMarketoftheShanghaiStockExchange,andtheRulesGoverningtheListingofSecuritiesonTheStockExchangeofHongKongLimited,dynamicallytrackspolicychangesandimprovesvarioussystemsaccordingly,therebyensuringtheeffectivenessofinstitutionalguidance.In2026,inlightofnewregulatoryrequirementsandtakingintoaccountitsactualcircumstances,theCompanyrevisedtheArticlesofAssociationandotherfiveinternalgovernancepolicies,namelythe“TermsofReferencefortheAuditCommittee”,the“TermsofReferencefortheCompensationCommittee”,the“TermsofReferencefortheNominationCommittee”,the“RulesofProcedureoftheBoard of Directors”and the “Rules of Procedure of the General Meeting”,andformulated one new internal governance policy, namely the “RemunerationManagement System for Directors and Senior Management of InnoCare PharmaLimited”.In2027,theCompanywillcontinuetotrackchangesinlaws,regulationsandregulatoryrules,andupdatethesystemsrelatingtocorporategovernanceinatimelymanner.
(2)InformationDisclosure
Intermsofinformationdisclosure,theCompanyhasestablishedstandardizedsystems such as the “Management Policies for Information Disclosure” and the“WorkingRulesforDomesticRepresentativesforInformationDisclosure”,andstrictlyfollowsitsinternalprocedures.In2026,nomajorerrorswereidentified,andtheCompanymadehigh-qualityinformationdisclosuretoinvestors.Atthesametime,basedonthecharacteristicsofthebiopharmaceuticalindustryandinvestorconcerns,theCompanyproactivelydiscloses,onavoluntarybasis,theclinicaltrialprogressandkeyR&Ddevelopmentsofmajorpipelineproductssuchasorelabrutinib,mesutoclax,fadeucravacitinib(ICP-488)andzurletrectinib(ICP-723),therebyfurtherenhancingR&Dtransparencyandhelpinginvestorspromptlygraspthedevelopmenttrendsandappreciatethelong-termvalueoftheGroup’sinnovativepipeline.TheCompanyhasreceivedan“A”ratingintheShanghaiStockExchange’sinformationdisclosureworkevaluationfortwoconsecutiveyears.In2027,theCompanywillstrengthenthequalityofinformationdisclosure,tightenthereviewofannouncementpreparation,andensurezeromajordisclosureerrorsandzerocorrections.TheCompanywillalso,withinthecomplianceframework,optimizetheinterpretationofoperatinginformation,enhancetheclarityofindicatorsandstrategicnarratives,reduceinformationasymmetry,andstabilizemarketexpectations.
(3)PerformanceofDutiesbytheAuditCommitteeoftheBoard
TheCompanycurrentlyfullyperformsthereviewandoversightresponsibilitiesoftheBoard’sAuditCommitteeovertheCompany’sfinancialreports,internalandexternalaudit,internalcontrolandothermatters.In2026,theCompanyheldatotaloffourmeetingsoftheBoard’sAuditCommittee,atwhichtheAuditCommitteeprovidedfullguidanceandreviewonmatterssuchastheCompany’sfinancialreports,internalandexternalaudit,andinternalcontrol.Duringtheauditoftheannualfinancialreport,theAuditCommitteealsoconductedfull-processguidance,oversightandinspectionofthe audit of the financial report through pre-audit, mid-audit and post-auditcommunicationmeetings, ensuring thatthe financialreport fairly, accuratelyandcompletelyreflectedtheCompany’sactualoperatingconditions.In2027,theCompanywillstrivetofurtherimprovethecorporategovernancestructure,effectivelyenhancethe Company’s governance standards, and establish more effective operational,managementandcontrolsystems.TheCompanywillholdnofewerthanfourAuditCommitteemeetingsthroughouttheyear,atwhichtheAuditCommitteewillperformitsreviewandoversightresponsibilitiesinrespectofmatterssuchascontrolworkduringtheannualfinancialreportauditperiod.AuditCommitteemembersshallreceivetrainingatleasttwiceayear.
III.Summary of Targets under the “Quality Improvement, EfficiencyEnhancementandHighReturn”ActionPlan
ThesummaryofthetargetsundertheCompany’s2027“QualityImprovement,EfficiencyEnhancementandHighReturn”ActionPlanisasfollows:
1.OperatingIndicatorsandActionPlan

IndicatorsCurrent Statusforthe FirstThree Quartersof 20262027 TargetPlanRisk
Growth rate of R&D investment16.12%≥ 10%Continue to invest in R&D, conduct regular pipeline reviews,andfocus on core project investment; refine project budget control and track actual progress; optimize the management of external procurement related to R&D expenses.Clinical trial enrollment, data, or approvals may not meet expectations, whichcouldcause fluctuationsinthe growth rate of R&D expenses. Thereisalsoarisk ofbiasinpipeline valuation,resulting in missed R&D opportunities or inefficient
    investment.
Number of new clinical trialsinitiated (including Phase I–III clinicaltrials, measured by first patient enrollment)14≥8Continue to advance the R&D and clinical development of various innovative drugs.The Company’s clinical trials are subject to numerous factors, including but not limited to the approvals of competent authorities, the numberofclinical trialsitesandtheir internalapprovals, patientenrollment, the formulation and execution of clinical trial protocols, cooperation with external third- party institutions, data processing and statistical analysis, and communications with regulatory authorities, which maydelayprogress
    and, in turn, prevent the Company from obtaining regulatory approval on schedule or commercializing candidatedrugsas planned.
2.ReturnandComplianceIndicatorsandActionPlans

IndicatorsCurrentStatus2027Plan
Investor relations managementCurrently, the Company has established a regular mechanism whereby results briefings are held after the disclosure of each periodic report.Continuously optimize communication channels for small and medium-sized investors and improve the quality of communication, regularly carry out investor engagement activities, and holdnofewerthanfourresults briefings.
ESG managementThe Company has disclosed ESG-relatedreports forseven consecutiveyears.Improve the system for collecting, compiling and disclosing ESG data and information,andcompletethe disclosure of the 2026 ESG Report with high quality;
  continue to optimize the Company’s greenhouse gas accountingsystemandexpand thescopeofcarbonemission measurement for Scope 3 categories.
Corporate governance policy developmentInresponsetonewregulatory requirements, the Company revised the Articles of Association and other five internal governance policies and formulated one new internalgovernancepolicy.Continuouslytrackchangesin laws, regulations and regulatoryrules,andupdatethe systems relating to corporate governanceinatimelymanner.
Information disclosureTheCompanyhascontinuedto implement high-standard management of information disclosure, optimize the presentationofannouncements, continuously enhance the readability of information disclosure, and improve the effectiveness of delivering value information. The Companyhasreceivedan“A” rating in the Shanghai Stock Exchange’s information disclosureworkevaluationfor twoconsecutiveyears.Strengthen the quality of informationdisclosure,tighten the review of announcement preparation, and ensure zero major disclosure errors and zero corrections. Within the compliance framework, optimizetheinterpretationof operatinginformation,enhance the clarity of indicators and strategic narratives, reduce information asymmetry and stabilizemarketexpectations.
Performance of duties by the Audit Committee of theBoardFullyperformthereviewand oversightresponsibilitiesofthe AuditCommitteeoftheBoard over the Company’s financial reports, internal and external audit,internalcontrolandother matters.The Audit Committee shall convene no fewer than four meetingsthroughouttheyear and perform its review and oversight responsibilities in respect of matters such as controlworkduringtheannual financial report audit period. The members of the Audit Committee shall receive trainingatleasttwiceayear.
IV.InvestorCommunicationChannels
TheCompanyhasestablishedamulti-channel,multi-tieredmechanismforroutineinvestor communication and engagement. Investors may communicate with theCompanyandprovidefeedbackthroughthefollowingchannels:
InvestorHotline:010-66609913
InvestorEmail:IR@innocarepharma.com
InteractivePlatform:SSEe-InteractionPlatformoftheShanghaiStockExchangeTheCompanywill,throughvariousmeanssuchasroutinetelephonecalls,emailcommunications,responsesviaSSEe-Interaction,andregularresultsbriefingsandcollectivereceptiondays,extensivelysolicitinvestors’opinionsandsuggestionsontheCompany’s business development and the “Quality Improvement, EfficiencyEnhancementandHighReturn”2.0ActionPlan,soastocontinuouslyenhancethequalityofthelistedcompanyandinvestorsatisfaction.
V. RiskWarningsandOtherNotes
TheaboveactionplanwasformulatedbytheCompanybasedonitscurrentoperations and the external environment. Its subsequent implementation may beaffectedbychangesindomesticandoverseasmarketconditions,industrypoliciesandotherfactors,andissubjecttocertainuncertainties.ItdoesnotconstituteacommitmentregardingtheCompany’sfutureoperatingresults.Investorsareadvisedtoexerciserationaljudgmentandpayattentiontoinvestmentrisks.
TheBoardofDirectorsofInnoCarePharmaLimited
21November2026

  中财网
各版头条